Moreover, we observed that the frequency of TSCM and CD57+ cells in the final CAR T cell product can be potentially exploited as predictive positive and negative biomarkers for CAR T cell expansion and anti-tumor efficacy in vivo. The gene discussed is B3GAT1; the disease is neoplasm.